Table 1.
Baseline characteristics and physiological parameters and laboratory features of patients with COVID-19 pneumonia who received Arbidol/IFN-α2b.
| Characteristics | IFN-α2b (n = 70) | Abidol/IFN-α2b (n = 71) | P |
|---|---|---|---|
| Age(y), mean (Range) | 53.2 (26–83) | 50.9 (24–75) | 0.543 |
| Sex (Male/Female), n (%) | 33(47.1)/37(52.9) | 41(57.7)/30(42.3) | 0.293 |
| Comorbidities | |||
| Hypertension, n (%) | 8 (11.4) | 7 (9.9) | 0.740 |
| Diabetes, n (%) | 7 (10.0) | 5 (7.0) | 0.113 |
| Othersa, n (%) | 5 (7.1) | 1 (1.4) | 0.113 |
| Clinical symptoms | |||
| Fever, n (%) | 40 (57.1) | 56 (81.2) | 0.003 |
| Cough, n (%) | 44 (62.9) | 32 (46.4) | 0.028 |
| Fatigue, n (%) | 9 (12.9) | 7 (10.1) | 0.998 |
| Shortness of breath, n (%) | 9 (12.9) | 7 (10.1) | 0.595 |
| Abdominal distension | 8 (11.4) | 7 (9.9) | 0.740 |
| Diarrhea, n (%) | 1 (1.4) | 4 (5.8) | 0.366 |
| Laboratory examinations | |||
| Decline in white blood cells, n (%) | 22 (31.4) | 20 (28.2) | 0.632 |
| Decline in lymphocytes, n (%) | 29 (41.4) | 22 (31.0) | 0.175 |
| Increase in aminotransferase, n (%) | 4 (5.7) | 11 (15.5) | 0.064 |
| Increase in creatine kinase, n (%) | 1 (1.4) | 6 (8.5) | 0.116 |
| Lung: total severity score | |||
| 1, <25% abnormality, n (%) | 29 (41.4) | 27 (38.0) | 0.124 |
| 2, 25%–50% abnormality, n (%) | 40 (57.1) | 44 (62.0) | |
| 3, 50%–75% abnormality, n (%) | 1 (1.4) | 2 (2.8) | |
| 4, ≥75% abnormality, n (%) | 0 (0) | 0 (0) | |
| SpO2, median (IQR) | 97.3 (93–99) | 97.3 (94–99) | 0.539 |
| Time from onset to be discharge, median (IQR) | 27.1 (8–53) | 24.2 (11–53) | 0.056 |
| Nucleus acid negative conversion time, median (IQR) | 23.8 (10–52) | 27.4 (7–52) | 0.057 |
| CT absorption time, mean (Range) | 16.7 (7–33) | 19.8 (10–36) | 0.037 |
Data are presented as no (%). For continuous variables, Mann–Whitney U test was used to calculate the P value. For categorical variables, χ2 test was used to calculate the P value.
a
Others included chronic heart diseases, arthrolithiasis, chronic hepatitis B.